Gargiulo, A.
6574  results:
?
3

Upadacitinib improves symptoms of concomitant allergic rhin..:

Gargiulo, L. ; Ibba, L. ; Piscazzi, F....
Journal of the European Academy of Dermatology and Venereology.  , 2024
 
?
5

Long‐term effectiveness and tolerability of apremilast in p..:

Gargiulo, L. ; Ibba, L. ; Malagoli, P....
Journal of the European Academy of Dermatology and Venereology.  , 2024
 
?
8

Manufacturing, testing and installation of the full tungste..:

Missirlian, M. ; Firdaouss, M. ; Richou, M....
Fusion Engineering and Design.  193 (2023)  - p. 113683 , 2023
 
?
9

Effectiveness and safety of upadacitinib for moderate‐to‐se..:

Gargiulo, L. ; Ibba, L. ; Piscazzi, F....
Journal of the European Academy of Dermatology and Venereology.  38 (2023)  2 - p. , 2023
 
?
 
?
11

A risankizumab super responder profile identified by long‐t..:

Gargiulo, L. ; Ibba, L. ; Malagoli, P....
Journal of the European Academy of Dermatology and Venereology.  38 (2023)  1 - p. , 2023
 
?
12

Pregnancy outcome of a patient treated with upadacitinib fo..:

Gargiulo, L. ; Ibba, L. ; Fiorillo, G....
Journal of the European Academy of Dermatology and Venereology.  38 (2023)  3 - p. , 2023
 
?
13

Effectiveness and safety of anti‐IL‐23 and anti‐IL‐17 biolo..:

Fiorillo, G. ; Ibba, L. ; Gargiulo, L....
Journal of the European Academy of Dermatology and Venereology.  37 (2023)  12 - p. , 2023
 
?
14

Risankizumab for the treatment of genital psoriasis: A 1‐ye..:

Orsini, D. ; Frascione, P. ; Assorgi, C....
Journal of the European Academy of Dermatology and Venereology.  38 (2023)  3 - p. , 2023
 
?
15

A combined VANDELS and LEGA-C study: the evolution of quies..:

Hamadouche, M L ; Carnall, A C ; McLure, R J...
Monthly Notices of the Royal Astronomical Society.  512 (2022)  1 - p. 1262-1274 , 2022
 
1-15